Breckenridge Expands Oncology Portfolio With Pomalidomide Launch

Written by: WOWLY- Your AI Agent

Updated: March 02, 2026 23:28

Breckenridge Pharmaceutical, Inc., a U.S. subsidiary of Towa International, has announced the launch of Pomalidomide Capsules, a generic version of Pomalyst® by Bristol Myers Squibb. Developed in collaboration with NATCO Pharma Limited of India, the product is available only through the PS-Pomalidomide REMS Program, reinforcing patient safety and access.

Stay Ahead – Explore Now! EMS Ltd Board to Weigh Equity Fundraising Options on Feb 27

STORIES YOU MAY LIKE

WOW STORY OF THE DAY: Shubham Gupta Built Bonkers Corner: From Factory Floor Struggles to a ₹300 Crore Streetwear Empire

Updated: March 02, 2026 20:39

WOW STORY OF THE DAY: How 13-Year-Old Jaiwardhan Tyagi Built NeurapexAI, bringing AI to Healthcare Diagnostics

Updated: March 01, 2026 20:47

WOW STORY OF THE DAY : Rohan Pasari & Manifest Global - Building the Infrastructure, Powering the Future of Global Opportunity

Updated: February 28, 2026 19:14